Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum
- PMID: 24938880
- PMCID: PMC4075993
- DOI: 10.1186/1471-2407-14-448
Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum
Abstract
Background: MicroRNAs (miRs) represent a distinct class of posttranscriptional modulators of gene expression with remarkable stability in sera. Several miRs are oncogenic (oncomiRs) and are deregulated in the pathogenesis of breast cancer and function to inhibit tumor suppressors. Routine blood monitoring of these circulating tumor-derived products could be of significant benefit to the diagnosis and relapse detection of early-stage breast cancer (EBC) patients.
Methods: Aim of this project was to determine expression of miR-155, miR-19a, miR-181b, miR-24, relative to let-7a in sera of 63 patients with EBC and 21 healthy controls. Longitudinal multivariate data analysis was performed to stochastically model the serum levels of each of the oncomiRs during disease phases: from diagnosis, after surgery, and following chemo/radiotherapy. Moreover, this analysis was utilized to evaluate oncomiR levels in EBC patients subgrouped using current clinical prognostic factors including HER2, Ki-67, and grade III.
Results: EBC patients significantly over-express the oncomiRs at the time of diagnosis. Following surgical resection the serum levels of miR-155, miR-181b, and miR-24 significantly decreased (p = 1.89e-05, 5.41e-06, and 0.00638, respectively) whereas the miR-19a decreased significantly after the therapy (p = 0.00869). Furthermore, in case of high-risk patients serum levels of miR-155, miR-19a, miR-181b, and miR-24 are significantly more abundant in comparison to low-risk group (p = 0.026, 0.02567, 0.0250, and 0.00990) and show a decreasing trend upon therapy.
Conclusions: OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
Figures

Similar articles
-
Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer.Int J Mol Sci. 2017 Oct 10;18(10):2116. doi: 10.3390/ijms18102116. Int J Mol Sci. 2017. PMID: 28994735 Free PMC article.
-
Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients.Sci Rep. 2018 Dec 19;8(1):17981. doi: 10.1038/s41598-018-36321-3. Sci Rep. 2018. PMID: 30568292 Free PMC article.
-
Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.BMC Cancer. 2018 Feb 6;18(1):141. doi: 10.1186/s12885-018-4020-7. BMC Cancer. 2018. PMID: 29409452 Free PMC article.
-
The role of oncomirs in the pathogenesis and treatment of breast cancer.Biomed Pharmacother. 2016 Mar;78:129-139. doi: 10.1016/j.biopha.2016.01.026. Epub 2016 Jan 24. Biomed Pharmacother. 2016. PMID: 26898434 Review.
-
The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.J Cell Physiol. 2018 Feb;233(2):774-786. doi: 10.1002/jcp.25813. Epub 2017 Mar 24. J Cell Physiol. 2018. PMID: 28109133 Review.
Cited by
-
The Roles of MicroRNAs in Breast Cancer.Cancers (Basel). 2015 Apr 9;7(2):598-616. doi: 10.3390/cancers7020598. Cancers (Basel). 2015. PMID: 25860815 Free PMC article. Review.
-
Regulation of breast cancer metastasis signaling by miRNAs.Cancer Metastasis Rev. 2020 Sep;39(3):837-886. doi: 10.1007/s10555-020-09905-7. Cancer Metastasis Rev. 2020. PMID: 32577859 Free PMC article. Review.
-
Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis.Int J Mol Sci. 2021 Apr 29;22(9):4697. doi: 10.3390/ijms22094697. Int J Mol Sci. 2021. PMID: 33946718 Free PMC article. Review.
-
Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication.Noncoding RNA. 2018 Dec 12;4(4):40. doi: 10.3390/ncrna4040040. Noncoding RNA. 2018. PMID: 30545127 Free PMC article. Review.
-
A systemic approach to screening high-throughput RT-qPCR data for a suitable set of reference circulating miRNAs.BMC Genomics. 2020 Jan 31;21(1):111. doi: 10.1186/s12864-020-6530-3. BMC Genomics. 2020. PMID: 32005151 Free PMC article.
References
-
- Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866. - PubMed
-
- Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–7070. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous